Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00273884 · ClinicalTrials.gov registry record · Phase 2
Amonafide in Combination With Cytarabine in Secondary AML
A Phase 2 study, sponsored by Xanthus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00273884: Completed Phase 2 study, sponsored by Xanthus Pharmaceuticals.
NCT00273884 is a Phase 2 study that has completed, run by Xanthus Pharmaceuticals. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00273884, a Phase 2 study, has completed, sponsored by Xanthus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
Interventions
- DRUG Cytarabine
- DRUG Amonafide L-Malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00273884
The ClinicalTrials.gov registry entry for NCT00273884 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xanthus Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT00273884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00273884 about?
NCT00273884 is a clinical study titled "Amonafide in Combination With Cytarabine in Secondary AML". This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
What is the current status of trial NCT00273884?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-08. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00273884?
The interventions under investigation include: Cytarabine (DRUG), Amonafide L-Malate (DRUG).
Who is sponsoring clinical trial NCT00273884?
This trial is sponsored by Xanthus Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.